Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases. The company's product pipeline includes VTP-300, VTP-200, VTP-1000, VTP-850 and VTP-1100. Barinthus Biotherapeutics plc, formerly known as Vaccitech plc, is based in OXFORD, United Kingdom.
| Revenue (Most Recent Fiscal Year) | $14.97M |
| Net Income (Most Recent Fiscal Year) | $-61.07M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.38 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -436.57% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -46.43% |
| Return on Assets (Trailing 12 Months) | -38.50% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.18 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.18 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.87 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.49 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.55 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.64 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 40.24M |
| Free Float | 35.93M |
| Market Capitalization | $44.26M |
| Average Volume (Last 20 Days) | 0.05M |
| Beta (Past 60 Months) | -0.80 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 25.20% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |